Montelucaste Farmoz (Montelukast)

Montelukast, the active ingredient in Montelucaste Farmoz, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It treats asthma, allergic rhinitis and exercise‑induced bronchoconstriction in adults and children.

GNH USA supplies Montelucaste Farmoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product is manufactured in the European Union under EU GMP standards and is available for export to regulated markets. Our supply chain ensures consistent quality and on‑time delivery to meet clinical demand.

Montelukast is used to manage conditions involving leukotriene‑mediated airway inflammation.

- Asthma: reduces frequency of bronchospasm, improves daytime symptom control and decreases reliance on rescue inhalers. - Allergic rhinitis: alleviates nasal congestion, sneezing, itchy eyes and post‑nasal drip. - Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity, allowing better exercise tolerance.

Montelukast may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort. - Cough: transient. - Diarrhea: loose stools. - Nasopharyngitis: mild upper respiratory infection symptoms. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Mood changes: depression, anxiety or suicidal thoughts. - Allergic reactions: angioedema, urticaria or anaphylaxis. - Hepatotoxicity: elevated liver enzymes or hepatitis. - Stevens‑Johnson syndrome: severe skin blistering. - Blood disorders: eosinophilia or neutropenia.

Before prescribing Montelucaste Farmoz, clinicians should consider several precautionary measures to ensure safe use. - Pregnancy: safety data are limited; use only if potential benefit justifies risk. - Breastfeeding: monitor infant for possible effects; decision based on risk‑benefit assessment. - Hepatic impairment: dose adjustment may be required; monitor liver function. - Concomitant asthma therapy: continue inhaled corticosteroids; do not replace controller meds. - Neuropsychiatric symptoms: observe for mood changes, depression or suicidal ideation. - Store at ambient temperature below 25°C: keep in original packaging, protect from moisture and direct sunlight.

Montelukast can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Phenobarbital: may reduce montelukast plasma concentrations. - Rifampin: induces metabolism leading to decreased effectiveness. - St. John’s wort: strong enzyme inducer that can lower drug levels.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): may increase risk of neuropsychiatric events. - Antifungal azoles (ketoconazole, itraconazole): can raise montelukast exposure. - Warfarin: monitor INR as occasional interaction reported.